Full Title
Phase II Open Label Prospective Nonrandomized Trial of Belumosudil for Switch-Maintenance Prophylaxis of Graft-versus-Host Disease in Allogeneic Hematopoietic Cell TransplantationPurpose
After a stem cell transplant, some patients develop a condition called graft-versus-host disease (GVHD). This occurs when the donor’s healthy immune cells see the recipient’s normal cells as foreign and begin to attack them.
GVHD can affect many parts of the body, including the skin, liver, stomach, intestines, joints, eyes, mouth, and lungs. It can range from mild to severe and is a common cause of reduced quality of life after a transplant.
This study aims to find out whether giving belumosudil, in addition to standard immunosuppressive therapy, can reduce GVHD risk. Belumosudil is an oral medication that works by blocking specific proteins that control immune system activity. By keeping the immune system in balance, belumosudil may help prevent GVHD. It will be given around day 100 after the transplant
If you take part in this study, you will get belumosudil as well as the usual treatment to prevent GVHD. This treatment includes tacrolimus with or without cyclophosphamide chemotherapy. Your doctor will let you know whether or not you will get cyclophosphamide.
Who Can Join
To join this study, there are a few conditions. You must:
- Have had an allogeneic stem cell transplant (from a donor) for blood cancer and received cyclophosphamide or abatacept treatment to prevent GVHD.
- Have received your stem cell transplant no more than 4 months before entering the study.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call Dr. Doris Ponce’s office at 646-608-3739.